Although many states' 2021 legislative sessions have already ended, we're still working on 100+ bills. While the pandemic slowed down most things, it certainly did not stop our progress fighting kidney disease! Learn more in our What's happening in the states blog post. READ MORE >>

As more health insurance companies adopt these new polices, an increasing number of patients, including kidney disease patients, are being negatively impacted because they are being forced to pay more money for their medications. READ MORE >>

The Trump administration released final rules that aim to encourage greater use of home dialysis and transplantation among Medicare beneficiaries and remove financial barriers to living organ donation. READ MORE >>

Throughout the pandemic, there have been significant gaps and inconsistencies in data showing COVID-19's impact on minorities. This data is essential in responding to a public health emergency, which is why we are advocating for better data. READ MORE >>

As Congress continues to debate the next COVID-19 relief package and the yearly spending bills, they should include bipartisan legislation in both the House and Senate to stop surprise bills. Surprise bills are unexpected bills consumers receive that are not covered by coinsurance, copays or premiums. READ MORE >>

As unemployment rates remain high and more people enroll in Medicaid as a result of the COVID-19 pandemic, costs will go up. We're advocating for increased federal funding and legislation that would ensure kidney patients have access to the health care. READ MORE >>

COVID-19 has greatly impacted state budgets, meaning big cuts to Medicare programs may be necessary. We asked Congress to enhance Medicaid funding so those who rely on it to manage kidney disease and other conditions can continue to have access to care. READ MORE >>

The American Kidney Fund (AKF) submitted a comment letter to the Center for Medicare & Medicaid Services (CMS) regarding their proposed rule on the End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC model). READ MORE >>

According to a new analysis from the U.S. Department of Health and Human Services (HHS), extending Medicare immunosuppressive drug coverage for kidney transplant recipients for more than three years post-transplant would result in Medicare savings of $73.4 million over 10 years. READ MORE >>

The Centers for Medicare and Medicaid Services (CMS) released a final rule that upholds the existing rules on the six protected classes of drugs in the Medicare Part D program. READ MORE >>

On April 3, the American Kidney Fund (AKF) hosted its annual Advocacy Day on Capitol Hill. Twenty-seven AKF Ambassadors from 19 states and the District of Columbia gathered in our nation’s capital to share their personal stories with kidney disease, and to advocate on key issues affecting kidney patients. READ MORE >>

To kick off National Minority Health Month, join the American Kidney Fund (AKF) for a briefing on the disproportionate impact of kidney disease on people of color and new research initiatives addressing kidney disease. READ MORE >>